To me the smartest thing for any prospective partner would be to try to nail down ALL uses for Brilacidin. If they were to do a deal for OM, then they would be in a less good position to negotiate for the IBD-related diseases -- because success of the OM would prove the viability of the drug, and other companies would potentially step up and start bidding. By getting rights NOW, the prospective partner would not see this scenario:

Company A markets Brilacidin-OM, the name Brilacidin becomes known (imagine the TV ads -- "avoid a serious and potentially fatal side effect of cancer treatment by using a simple mouth rinse...."
Company B thinks: hey, people already know the brand name Brilacidin, now we can capitalize on THEIR publicity to market the IBD-related drugs..... let's bid high and WE will bring other formulations to market.

The only thing that surprises me is that they didn't also include the antibiotic use. If I were doing the negotiating, I'd want to be sure that no one else can market Brilacidin for anything else.